Integrative analysis of methylation and transcriptomic profiles during treatment
tumor
TUMOR
The availability of the longitudinal sampling of tumor biopsies gave us the opportunity to evaluate the immune-modulatory effect of the HMA during therapy. Although NIBIT-M4 trial was not designed to compare the effect of the combination HMA plus ICI vs. ICI alone, we could evaluate the changes of the methylation pattern induced by the treatment with the HMA. When we considered the overall methylation level across the genome, a trend towards global demethylation was observed for both R and NR patients (Supplementary Fig 